The Relationship Between ALDH2 and Aortic Dissection (RALAD)

February 1, 2019 updated by: Qilu Hospital of Shandong University
The purpose of this study is to evaluate the impact of ALDH2 Glu504Lys polymorphism on aortic dissection.

Study Overview

Status

Unknown

Conditions

Study Type

Observational

Enrollment (Anticipated)

400

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Shandong
      • Jinan, Shandong, China, 250012
        • Recruiting
        • Qilu Hospital of Shandong University
        • Contact:
        • Principal Investigator:
          • Yuguo Chen, M.D., Ph.D.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Consecutive patients diagnosed with aortic dissection in Qilu Hospital.

Description

Inclusion Criteria:

  • Chinese Han people diagnosed with aortic dissection in Qilu Hospital

Exclusion Criteria:

  • Aortic dissection based on trauma, connective tissue diseases and pregnancy
  • Patients with tumor
  • Patients with no written consensus

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Control
Chinese Han people undergoing coronary angiography in Qilu Hospital in corresponding period whose coronary arteries narrowing less than 50 percent.
Aortic dissection
Chinese Han people diagnosed with aortic dissection in Qilu Hospital

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of patients with different ALDH2 genotype
Time Frame: 1-30 days after samples collected
DNA was extracted from venous blood;genomic DNA underwent PCR amplification; finally, PCR products were purified and directly sequenced by Invitrogen Corp or Biosune Corp.Then ALDH2 genotype was distinguished depend on a G-to-A missense mutation on exon 12 of ALDH2 gene.
1-30 days after samples collected

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Concentration of inflammatory factors in blood and aortic specimen
Time Frame: 1-30 days after samples collected
Concentration of 4-HNE、MMP-2、MMP-9 detected by elisa kit、IHC or western blot in relevant specimen.
1-30 days after samples collected
ALDH2 activity
Time Frame: 1-30 days after samples collected
Activity of ALDH2 was detected in blood and aortic specimen depend on its reducibility of NAD+
1-30 days after samples collected

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Qilu Hospital of Shandong University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2015

Primary Completion (Anticipated)

December 1, 2019

Study Completion (Anticipated)

December 1, 2019

Study Registration Dates

First Submitted

December 7, 2015

First Submitted That Met QC Criteria

December 10, 2015

First Posted (Estimate)

December 15, 2015

Study Record Updates

Last Update Posted (Actual)

February 5, 2019

Last Update Submitted That Met QC Criteria

February 1, 2019

Last Verified

December 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2015QLMS37

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Aortic Dissection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe